Stephen Krahling was a published cancer researcher when vaccine maker Merck brought him on board as a virologist in 1999. That’s when he says he found himself embroiled in an all-hands-on-deck ...

The FDA has approved a new pneumococcal vaccine from Merck & Co, just over a month after Pfizer got a green light for a new version of its market leading Prevnar shot. Merck's Vaxneuvance ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

It will compete with Merck & Co's equally well-established MMR II vaccine in the US, which has had the market mostly to itself since it was approved by the FDA in the 1970s, as well as Merck's ...

A personalized vaccine demonstrated the potential to induce long-lasting immune response among people with advanced kidney ...

Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or ...

Kennedy can provide doctors and healthcare professionals with the information they need to truly determine if a drug is safe, ...

Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

Preparations for submission of a Biologics License Application (BLA) for Cylembio® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end 2025 remain on track. The trial completed enrollment in ...

AbbVie made a $350 million upfront payment to Gubra for rights to the drug, called GUB014295. Gubra is also eligible to receive another $1.9 billion if certain development and sales milestones are met ...

The global viral vectors for non-human primates market was valued at USD 145.8 Mn in 2023 and is projected to grow at a CAGR ...